Minimal Residual Disease Detected Prior to Hematopoietic Cell Transplantation

被引：11

作者：

Foster, Jennifer H. ^{[2
]}

Hawkins, Douglas S.

Loken, Michael R. ^{[1
,3
]}

Wells, Denise A. ^{[3
]}

Thomson, Blythe ^{[1
]}

机构：

[1] Seattle Childrens, Div Pediat Hematol Oncol, Seattle, WA USA

[2] Baylor Coll Med, Texas Childrens Canc Ctr, Dept Pediat Hematol Oncol, Houston, TX 77030 USA

[3] HematoLogics Inc, Seattle, WA USA

来源：

PEDIATRIC BLOOD & CANCER | 2011年 / 57卷 / 01期

关键词：

ALL; molecular diagnosis and therapy; minimal residual disease; transplantation; ACUTE LYMPHOBLASTIC-LEUKEMIA; BONE-MARROW-TRANSPLANTATION; FLOW-CYTOMETRY; CHILDREN; RELAPSE; PROGNOSIS; MRD;

D O I：

10.1002/pbc.23079

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Previous studies to evaluate minimal disease in acute lymphoblastic leukemia (ALL) after treatment have relied on the diagnostic specimen to develop patient-specific analytical probes. The diagnostic specimen is often not available in a tertiary setting; therefore, we evaluated the use of flow cytometry (FCM) using a "difference from normal'' approach to detect residual disease prior to myeloablative allogeneic hematopoietic cell transplantation (HCT). Among 116 pediatric patients with ALL who were in morphological remission at time of transplant, we found that those patients who had detectable residual disease by FCM prior to HCT experienced significantly inferior outcome. Pediatr Blood Cancer 2011;57:163-165. (C) 2011 Wiley-Liss, Inc.

引用

页码：163 / 165

页数：3

共 19 条

[1] Prognostic Value of Minimal Residual Disease Quantification Before Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia: The ALL-REZ BFM Study Group [J].

Bader, Peter ;

Kreyenberg, Hermann ;

Henze, Guenter H. R. ;

Eckert, Cornelia ;

Reising, Miriam ;

Willasch, Andre ;

Barth, Andrea ;

Borkhardt, Arndt ;

Peters, Christina ;

Handgretinger, Rupert ;

Sykora, Karl-Walter ;

Holter, Wolfgang ;

Kabisch, Hartmut ;

Klingebiel, Thomas ;

von Stackelberg, Arend .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (03) :377-384

[2] Graft-versus-leukemia effect in acute lymphoblastic leukemia: the importance of tumor burden and early detection [J].

Bradfield, SM ;

Radich, JP ;

Loken, MR .

LEUKEMIA, 2004, 18 (06) :1156-1158

[3] Role of Minimal Residual Disease Monitoring in Adult and Pediatric Acute Lymphoblastic Leukemia [J].

Campana, Dario .

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2009, 23 (05) :1083-+

[4] Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia [J].

Kang, Huining ;

Chen, I. -Ming ;

Wilson, Carla S. ;

Bedrick, Edward J. ;

Harvey, Richard C. ;

Atlas, Susan R. ;

Devidas, Meenakshi ;

Mullighan, Charles G. ;

Wang, Xuefei ;

Murphy, Maurice ;

Ar, Kerem ;

Wharton, Walker ;

Borowitz, Michael J. ;

Bowman, W. Paul ;

Bhojwani, Deepa ;

Carroll, William L. ;

Camitta, Bruce M. ;

Reaman, Gregory H. ;

Smith, Malcolm A. ;

Downing, James R. ;

Hunger, Stephen P. ;

Willman, Cheryl L. .

BLOOD, 2010, 115 (07) :1394-1405

[5] NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].

KAPLAN, EL ;

MEIER, P .

JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481

[6] Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR [J].

Kerst, G ;

Kreyenberg, H ;

Roth, C ;

Well, C ;

Dietz, K ;

Coustan-Smith, E ;

Campana, D ;

Koscielniak, E ;

Niemeyer, C ;

Schlegel, PG ;

Müller, I ;

Niethammer, D ;

Bader, P .

BRITISH JOURNAL OF HAEMATOLOGY, 2005, 128 (06) :774-782

[7] Minimal residual disease status as a predictor of relapse after allogeneic bone marrow transplantation for children with acute lymphoblastic leukaemia [J].

Knechtli, CJC ;

Goulden, NJ ;

Hancock, JP ;

Harris, EL ;

Garland, RJ ;

Jones, CG ;

Grandage, VLG ;

Rowbottom, AW ;

Green, AF ;

Clarke, E ;

Lankester, AW ;

Potter, MN ;

Cornish, JM ;

Pamphilon, DH ;

Steward, CG ;

Oakhill, A .

BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (03) :860-871

[8] Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia [J].

Knechtli, CJC ;

Goulden, NJ ;

Hancock, JP ;

Grandage, VLG ;

Harris, EL ;

Garland, RJ ;

Jones, CG ;

Rowbottom, AW ;

Hunt, LP ;

Green, AF ;

Clarke, E ;

Lankester, AW ;

Cornish, JM ;

Pamphilon, DH ;

Steward, CG ;

Oakhill, A .

BLOOD, 1998, 92 (11) :4072-4079

[9] Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia:: a report of the Pre-BMT MRD Study Group [J].

Krejci, O ;

van der Velden, VHJ ;

Bader, P ;

Kreyenberg, H ;

Goulden, N ;

Hancock, J ;

Schilham, MW ;

Lankester, A ;

Révész, T ;

Klingebiel, T ;

van Dongen, JJM .

BONE MARROW TRANSPLANTATION, 2003, 32 (08) :849-851

[10]

LOKEN MR, 1987, BLOOD, V70, P1316

← 1 2 →